Coen van Hasselt
Hoogleraar Farmacologie
- Naam
- Prof.dr. J.G.C. van Hasselt
- Telefoon
- +31 71 527 3266
- coen.vanhasselt@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-1664-7314
Meer informatie op de Engelstalige pagina.
Promovendi
Nieuws
-
Een miljoen euro voor slimme combi’s van antibiotica – tegen hardnekkige infecties én resistentie -
Een nieuwe kijk op longontsteking: wat vertelt ons lichaam zelf over de oorzaak? -
Bij de volgende pandemie versnelt dit wiskundig model de zoektocht naar een behandeling -
Antibiotica uit de natuur verbeteren -
Hoe je betrouwbaar onderzoek kunt doen met virtuele patiënten -
NWO Open Science Fund subsidies voor vijf Leidse projecten -
Nieuwe behandelingen voor levensbedreigende ziekte sepsis -
Kinderen worden bacteriën om te leren over antibiotica -
Onderzoekers gaan de strijd aan met antibioticaresistente bacteriën -
Samen de strijd aan met antibioticaresistentie -
Leidse onderzoekers slaan handen ineen tegen tuberculose -
Antibioticaresistentie op een slimme manier bestrijden
-
Behandeling verbeteren voor pasgeboren baby’s met sepsis -
Toch naar het lab voor je masterproject dankzij automatisering -
Twee keer KNMP Studentenprijs voor Leidse studenten -
Leidse doseringsapp voor coronamedicatie haalt internationale pers -
App helpt artsen met de juiste dosering corona-medicatie -
Een headset en voldoende koffie: thuiswerken in tijden van corona -
Stem op de Ontdekker van het Jaar -
Coen van Hasselt over antibioticaresistentie op Radio 1 -
Coen van Hasselt op BNR Nieuwsradio over antibioticaresistentie -
Nieuwe doseringsschema’s om antibioticaresistentie terug te dringen
-
Nieuwe doseringsschema’s om antibioticaresistentie terug te dringen
-
Boven de pot snuiven
Postdocs
Hoogleraar Farmacologie
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Mehta K.M., Guo T. & Graaf P.H. van der Hasselt J.G.C. van (2024), Model‐based dose optimization framework for bedaquiline, pretomanid, and linezolid for the treatment of drug‐resistant tuberculosis, British Journal of Clinical Pharmacology 90(2): 463-474.
- Tandar S.T., Aulin L.B.S., Leemkuil E. M.J., Liakopoulos A. & Hasselt J.G.C. van (2024), Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations, Journal of Pharmacokinetics and Pharmacodynamics 51: 199-211.
- Zwep L.B., Guo T., Nagler T.W., Knibbe C.A.J., Meulman J.J. & Hasselt J.G.C. van (2024), Virtual patient simulation using copula modeling, Clinical Pharmacology & Therapeutics 115(4): 795-804.
- Higazy D., Pham A.D., Hasselt C. van, Høiby N, Jelsbak L., Moser C. & Ciofu O. (2024), In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection, The ISME Journal 18(1): wrae036.
- Mehta K.M., Balazki P., Graaf P.H. van der, Guo T. & Hasselt J.G.C. van (2024), Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 63: 657-668.
- Budda D., Gülave B., Hasselt J.G.C. van & Lange E.C.M. de (2024), Non‐linear blood–brain barrier transport and dosing strategies influence receptor occupancy ratios of morphine and its metabolites in pain matrix, British Journal of Pharmacology 181(20): 3856-3868.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2024), Corrigendum to “Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?” , European Journal of Pharmaceutical Sciences 196: 106736.
- Guo Y., Guo T., Knibbe C.A.J., Zwep L.B. & Hasselt J.G.C. van (2024), Generation of realistic virtual adult populations using a model-based copula approach, Journal of Pharmacokinetics and Pharmacodynamics 51: 735-746.
- Os W. van, Pham A.D., Eberl S., Minichmayr I.K., Hasselt J.G.C. van & Zeitlinger M. (2024), Integrative model-based comparison of target site-specific antimicrobial effects: a case study with ceftaroline and lefamulin, International Journal of Antimicrobial Agents 63(5): 107148.
- Herzberg C., Meegen E.N. van & Hasselt J.G.C. van (2024), Interplay of virulence factors shapes ecology and treatment outcomes in polymicrobial infections, Mathematical Biosciences 377: 109293.
- Hartog I. den, Zwep L.B., Meulman J.J., Hankemeier T., Garde E.M.W. van de & Hasselt J.G.C. van (2024), Longitudinal metabolite profiling of Streptococcus pneumoniae-associated community-acquired pneumonia, Metabolomics 20(2): 35.
- Yin A., Veerman G.D.M., Hasselt J.G.C. van, Steendam C.M.J., Dubbink H.J.,Guchelaar H.‐J., Friberg L.E., Dingemans A.‐M.C., Mathijssen R.H.J. & Moes D.J.A.R. (2024), Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib, CPT: Pharmacometrics & Systems Pharmacology 13(4): 612-623.
- Maagdenberg H.W. van den, Šícho Martin A.D.A., Luukkonen S., Schoenmaker L., Jespers M., Béquignon O.J.M., Gorostiola González M.G., Broek R.L van den, Bernatavicius R., Hasselt J.G.C.van, Graaf P.H. van der & Westen G.J.P. van (2024), QSPRpred: a flexible open-source quantitative structure-property relationship modelling tool, Journal of Cheminformatics 16: 128.
- Os W. van, Nussbaumer-Pröll A., Pham A.D., Wijnant G.J., Ngougni Pokem P., Bambeke F. Van, Hasselt J.G.C. van & Zeitlinger M. (2024), Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections, Journal of Antimicrobial Chemotherapy 79(10): 2484-2492.
- Sanz-Codina M., Os W. van, Pham A.D., Jorda A., Wölfl-Duchek M., Bergmann F., Lackner E., Lier C., Hasselt J.G.C. van, Minichmayr I.K., Dorn C., Zeitlinger M. & Al Jalali V. (2024), Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers, Journal of Antimicrobial Chemotherapy 79(12): 3281-3288.
- Groesen E. van, Mons M.W.E., Kotsogianni A.I., Arts M., Tehrani K.H.M.E., Wade N., Lysenko V., Stel F.M., Zwerus J.T., De Benedetti S., Bakker A.T., Chakraborty P., Stelt M. van der, Scheffers D.-J., Gooskens J., Smits W.K., Holden K., Gilmour P., Willemse J.J., Hitchcock C.A., Hasselt J.G.C. van & Schneider T. Martin N.I. (2024), Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity, Science Translational Medicine 16(759): eabo4736.
- Troisi C., Cojutti P.G., Rinaldi M.,Tonetti T., Siniscalchi A., Hasselt J.G.C. van, Viale P. & Pea F. (2024), Impact of continuous infusion meropenem PK/PD target attainment on C-reactive protein dynamics in critically ill patients with documented gram-negative hospital-acquired or ventilator-associated pneumonia, Clinical Pharmacokinetics 63(11): 1573-1583.
- Kok M., Hankemeier T. & Hasselt J.G.C. van (2024), Nutrient conditions affect antimicrobial pharmacodynamics in Pseudomonas aeruginosa, Microbiology Spectrum : .
- Bock M., Theut A.M., Hasselt J.G.C. van, Wang H., Fuursted K., Høiby N., Lerche C.J., Ihlemann N., Gill S., Christiansen U., Nielsen H.L., Lemming L., Elming H., Povlsen J.A., Bruun N.E., Høfsten D., Fosbøl E.L., Køber L., Schultz M., Pries-Heje M.M., Kristensen J.H, Christensen J.J., Rosenvinge F.S., Pedersen C.T., Helweg-Larsen J., Tønder N., Iversen K., Bundgaard H. & Moser C. (2023), Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a POET substudy, Clinical Infectious Diseases 77(2): 242-251.
- Hartog I. den, Karu N., Zwep L.B., Voorn P.G., Garde E.M.W. van de, Hankemeier T. & Hasselt C.J.G. van (2023), Differential metabolic host response to pathogens associated with community-acquired pneumonia, Metabolism open 18: 100239.
- Gülave B., Budda D., Saleh M.A.A.E.W., Hasselt J.G.C. van & Lange E.C.M. de (2023), Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?, European Journal of Pharmaceutical Sciences 187: 106482.
- Fu Y., Snelder N., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Evaluation of a cardiovascular systems model for design and analysis of hemodynamic safety studies, Pharmaceutics 15(4): 1175.
- Mehta K.M., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 62(3): 519-532.
- Janssen J.M., Damoiseaux D., Hasselt J.G.C. van, Amant F.C.H., Calsteren K., Beijnen J.H., Huitema A.D.R. & Dorlo T.P.C. (2023), Semi-physiological enriched population pharmacokinetic modelling to predict the effects of pregnancy on the pharmacokinetics of cytotoxic drugs, Clinical Pharmacokinetics 62(8): 1157-1167.
- Bock M., Hasselt J.G.C. van, Schwartz F., Wang H., Høiby N., Fuursted K., Ihlemann N., Gill S., Christiansen U., Bruun N.E., Elming H., Povlsen J.A., Køber L., Høfsten D.E., Fosbøl E.L., Pries-Heje M.M., Christensen J.J., Rosenvinge F.S., Torp-Pedersen C., Helweg-Larsen J., Tønder N., Iversen K., Bundgaard H. & Moser C. (2023), Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis, Journal of Antimicrobial Chemotherapy 78(12): 2840–2848.
- Liu F., Aulin L.B.S. & Manson M.L. Krekels E.H.J. Hasselt J.G.C. van (2023), Unraveling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-mediated metabolism, European Journal of Drug Metabolism and Pharmacokinetics 48: 623–631.
- Mehta K.M., Spaink H.P., Ottenhoff T.H.M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches, Trends in Pharmacological Sciences 43(4): 293-304.
- Liakopoulos A., Aulin L.B.S., Buffoni M., Fragkiskou E., Hasselt J.G.C. van & Rozen D.E. (2022), Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution, Proceedings of the National Academy of Sciences 119(18): e2121768119.
- Fu Y., Taghvafard H., Said M.M., Rossman E.I., Collins T.A., Billiald-Desquand S., Leishman D., Graaf P.H. van der, Hasselt J.G.C. van & Snelder N. (2022), A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables, CPT: Pharmacometrics and Systems Pharmacology 11(5): 640-652.
- Vinkenoog M., Steenhuis M., Brinke A. ten, Hasselt J.G.C. van: Janssen M.P., Leeuwen M. van, Swaneveld F.H., Vrielink H., Watering L. van de, Quee F., Hurk K. van den, Rispens T., Hogema B. & Schoot C.E. van der (2022), Associations between symptoms, donor characteristics and IgG antibody response in 2082 COVID-19 convalescent plasma donors, Frontiers in Immunology 13: 821721.
- Guo T., Abdulla A., Koch B.C.P., Hassel J.G.C. van, Endeman H., Schouten J.A., Elbers P.W.G., Brüggeman R.J.M. & Hest R.M. (2022), Pooled population pharmacokinetic analysis for exploring ciprofloxacin pharmacokinetic variability in intensive care patients, Clinical Pharmacokinetics 61(6): 869-879.
- Kok M., Maton L., Peet M.P. van der, Hankemeier T. & Hasselt J.G.C. van (2022), Unraveling antimicrobial resistance using metabolomics, Drug Discovery Today 27(6): 1774-1783.
- Aulin L.B.S., Kleijburg A., Moerland M. & Hasselt J.G.C. van (2022), Characterizing the kinetics of presepsin and associated inflammatory biomarkers in human endotoxemia, Inflammation Research 71(9): 999-1001.
- Liu F., Aulin L.B.S., Guo T., Krekels E.H.J., Moerland M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations, British Journal of Clinical Pharmacology 88(12): 5420-5427.
- Liu F., Aulin L.B.S., Kossen S.S.A., Cathalina J.E.J., Bremmer M., Foks A.C., Graaf P.H. van den Moerland M. & Hasselt J.G.C. van (2022), A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis, Journal of Pharmacokinetics and Pharmacodynamics 49(6): 645-655.
- Maas P., Hartog I. den, Kindt A.S.D., Boman S., Hankemeier T. & Hasselt J.G.C. van (2022), The Immunometabolic Atlas: a tool for design and interpretation of metabolomics studies in immunology, PLoS ONE 17(5): e0268408.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J.A.R. (2022), Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4206.
- Aulin L.B.S., Tandar S.T., Zijp T. van, Ballegooie E. van, Graaf P.H. van der, Saleh M.A.A.E.W., Välitalo P. & Hasselt J.G.C. van (2022), Physiologically based modelling framework for prediction of pulmonary pharmacokinetics of antimicrobial target site concentrations, Clinical Pharmacokinetics 61: 1735-1748.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J. (2022), Publisher correction: anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4879 (4879).
- Mehta K.M., Guo T., Wallis R.S., Graaf P.H. van der & Hasselt J.G.C. van (2022), Quantitative systems pharmacology modeling framework of autophagy in tuberculosis: application to adjunctive metformin host-directed therapy, Antimicrobial Agents and Chemotherapy 66(8): e0036622.
- Aulin L.B.S., De Paepe. P., Dhont E., Jaeger A. de, Vande Walle J., Vandenberghe W., McWhinney B.C., Ungerer J.P.J., Hasselt J.G.C. van & Cock P.A.J.G. de (2021), Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients, Clinical Pharmacokinetics 60: 353-363.
- Aulin L.B.S., Koumans C.I.M., Haakman Y., Os W. van, Kraakman M.E.M., Gooskens J., Smits W.K., Liakopoulos A. & Hasselt J.G.C. van (2021), Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae, Journal of Antimicrobial Chemotherapy 76(2): 533-535.
- Zwep L.B., Duisters K.L.W., Jansen M., Guo T., Meulman J.J., Upadhyay P. & Hasselt J.G.C. (2021), Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling, CPT: Pharmacometrics and Systems Pharmacology 10(4): 350-361.
- Aulin L.B.S., Lange D.W. de, Saleh M.A.A., Graaf P.H. van der, Völler S. & Hasselt J.G.C. (2021), Biomarker-guided individualization of antibiotic therapy, Clinical Pharmacology & Therapeutics 110(2): 346-360.
- Thomson K.M., Dyer C., Liu F., Sands K., Portal E., Carvalho M.J., Barrell M., Boostrom I., Dunachie S., Farzana R., Ferreira A., Frayne F., Hassan B., Jones E., Jones L., Mathias J., Milton R., Rees J., Chan G.J., Bekele D., Mahlet A., Basu S., Nandy R.K., Saha B., Iregbu K., Modibbo F., Uwaezuoke S., Zahra R., Shirazi H., Syed N.U., Mazarati J.B., Rucogoza A., Gaju L., Mehtar S., Bulabula A.N.H., Whitelaw A., Hasselt J.G.C. van & Walsh T.R. (2021), Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS), Lancet Infectious Diseases 21(12): 1677-1688.
- Rahman R., Zatorski N., Hansen J., Xiong Y., Hasselt J.G.C. van, Sobie E.A., Birtwistle M.R., Azeloglu E.U., Iyengar R. & Schlessinger A. (2021), Protein structure-based gene expression signatures, Proceedings of the National Academy of Sciences 118(19): e2014866118.
- Keij F.M., Koch B.E.V., Lozano Vigario F., Simons S.H.P., Hasselt J.G.C. van, Knibbe C.A.J., Spaink H.P., Reiss I.K.M. & Krekels E.H.J. (2021), Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis, Journal of Clinical and Translational Science 5(1): e140.
- Hartog I. den, Zwep L.B., Vestjens S.M.T., Harms A.C., Voorn G.P., Lange D.W. de, Bos W.J.W., Hankemeier T., Garde E.M.W. & Hasselt J.G.C. van (2021), Metabolomic profiling of microbial disease etiology in community-acquired pneumonia, PLoS ONE 16(6): e0252378.
- Aulin L.B.S., Liakopoulos A., Graaf P.H. van der, Rozen D.E. & Hasselt J.G.C. (2021), Design principles of collateral sensitivity-based dosing strategies, Nature Communications 12: 5691.
- Poppe M., Clodi C., Schriefl C., Mueller M., Sunder-Plaßmann R., Reiter B., Rechenmacher M., Os W. van., Hasselt J.G.C., Holzer M., Herkner H., Schwameis M., Jilma B., Schoergenhofer C. & Weiser C. (2021), Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - a probe drug of CYP2C19 metabolism, Biomedicine & Pharmacotherapy 146: 112573.
- Zwep L.B., Haakman Y., Duisters K.L.W., Meulman J.J., Liakopoulos A. & Hasselt J.G.C. van (2021), Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data, JAC-Antimicrobial Resistance 3(4): dlab175.
- Fu Y., Snelder N., Graaf P.H. van der & Hasselt J.G.C. van (2020), Hemodynamic simulator: a shiny web application for predicting drug effect on hemodynamics, Journal of Pharmacological and Toxicological Methods 105: 23.
- Fu Y., Snelder N., Taghvafard H., Graaf P.H. van der & Hasselt J.G.C. van (2020), Hemodynamic systems model to characterize cardiovascular drug effects, Journal of Pharmacological and Toxicological Methods 105: 23.
- Hasselt J.G.C. van, Rahman R., Hansen J., Stern A., Shim J.V., Xiong Y., Pickard A., Jayaraman G., Hu B., Mahajan M., Gallo J.M., Goldfarb J., Sobie E.A., Birtwistle M.R., Schlessinger A., Azeloglu E.U. & Iyengar R. (2020), Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity, Nature Communications 11: 4809.
- Guo T.J., Hest R.M. van, Zwep L.B., Roggeveen L.F., Fleuren L.M., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Elbers P.W.G. & Hasselt J.G.C. van (2020), Optimizing predictive performance of bayesian forecasting for vancomycin concentration in intensive care patients, Pharmaceutical Research 37: 171.
- Guo T.J., Hest R.M. van, Fleuren L.M., Roggeveen L.F., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Hasselt J.G.C. van & Elbers P.W.G. (2020), Why we should sample sparsely and aim for a higher target: lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients, British Journal of Clinical Pharmacology 87(3): 1234-1242.
- Yu H., Janssen J.M., Sawicki E. Hasselt J.G.C. van, Weger V.A. de, Nuijen B., Schellens J.H.M., Beijnen J.H. & Huitema A.D.R. (2020), A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development, The Journal of Clinical Pharmacology 60(3): 340-350.
- Centanni M., Moes D.J.A.R., Trocóniz I.F., Ciccolini J. & Hasselt J.G.C. van (2019), Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors, Clinical Pharmacokinetics 58(7): 835-857.
- Hasselt J.G.C. van & Iyengar R. (2019), Systems Pharmacology: Defining the Interactions of Drug Combinations, Annual Review of Pharmacology and Toxicology 59: 21-40.
- Calizo R.C., Bhattacharya S., Hasselt J.G.C. van, Wei C., Wong J.S., Wiener R.J., Ge X., Wong N.J., Lee J.J., Cuttitta C.M., Jayaraman G., Au V.H., Janssen W., Liu T., Li H., Salem F., Jaimes E.A., Murphy B., Campbell K.N. & Azelogu E.U. (2019), Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity, Nature Communications 10: 2061.
- Yin A., Yamada A., Stam W.B., Hasselt J.G.C. van & Graaf P.H. van der (2018), Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction, British Journal of Pharmacology 175(16): 3394-3406.
- Illamola S.M., Sherwin C.M. & Hasselt J.G.C. van (2018), Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses, Clinical Pharmacokinetics 57(10): 1217-1228.
- Vries Schultink A.H.M. de, Boekhout A.H., Gietema J.A., Burylo A.M., Dorlo T.P.C., Hasselt J.G.C. van, Schellens J.H.M. & Huitema A.D.R. (2018), Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens, Journal of Pharmacokinetics and Pharmacodynamics 45(3): 431-442.
- Aulin L.B.S., Valitalo P.A., Rizk M.L., Visser S.A.G., Rao G., Graaf P.H. van der & Hasselt J.G.C. van (2018), Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans, Pharmaceutical Research 35(2): 26.
- Ramamoorthy A., Sadler B.M., Hasselt J.G.C. van, Elassaiss J., Kasichayanula S, Edwards A.Y., Graaf P.H. van der, Zhang L & Wagner J.A. (2018), Crowdsourced Asparagus Urinary Odor Population Kinetics, CPT: Pharmacometrics and Systems Pharmacology 7(1): 34-41.
- Saleh M.A.A.E.W., Garde E.M.W. van de & Hasselt J.G.C. van (2018), Host-response biomarkers for the diagnosis of bacterial respiratory tract infections, Clinical Chemistry and Laboratory Medicine 57(4): 442-451.
- Yamamoto Y., Välitalo P.A., Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Kokki H., Kokki M., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2018), Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach, European Journal of Pharmaceutical Sciences 112: 168-179.
- Yamamoto Y., Välitalo P.A., Berg D.J. van den, Hartman R.J., Brink W. van den, Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Bakshi S.D., Aranzana-Climent V., Marchand S., Dahyot-Fizelier C., Couet W., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations, Pharmaceutical Research 34(2): 333–351.
- Nguyen T.H.T., Mouksassi M.S., Holford N., Al-Huniti N., Freedman I., Hooker A.C., John J., Karlsson M.O., Mould D.R., Pérez Ruixo J.J., Plan E.L., Savic R., Hasselt J.G.C. van, Weber B., Zhou C., Comets E. & Mentré F. (2017), Model evaluation of continuous data pharmacometric models: Metrics and graphics, CPT: Pharmacometrics and Systems Pharmacology 6(2): 87-109.
- Yamamoto Y., Valitalo P.A.J., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Berg D.J. van den, Hartman R.J., Wong Y.C., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model, CPT: Pharmacometrics and Systems Pharmacology 6(11): 765–777.
- Kohler I., Hankemeier T., Graaf P.H. van der, Knibbe C.A.J. & Hasselt J.G.C. van (2017), Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine, European Journal of Pharmaceutical Sciences 109: S15-S21.
- Goulooze S.C., Krekels E.H.J., Dijk M. van, Tibboel D., Graaf P.H. van der, Hankemeier T., Knibbe C.A.J. & Hasselt J.G.C. van (2017), Towards personalized treatment of pain using a quantitative systems pharmacology approach, European Journal of Pharmaceutical Sciences 109: S32-S38.
- Krekels E.H.J., Hasselt J.G.C. van, Anker J.N. van den, Allegaert K., Tibboel D. & Knibbe C.A.J. (2017), Evidence-based drug treatment for special patient populations through model-based approaches, European Journal of Pharmaceutical Sciences 109(Supplement): S22-S26.
- Hasselt J.G. van, Rizk M.L., Lala M., Chavez-Eng C., Visser S.A., Kerbusch T., Danhof M., Rao G. & Graaf P.H. van der (2016), Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid, British Journal of Clinical Pharmacology 81: 1113–1123.
- Jacobs B.A., Deenen M.J, Pluim D, Hasselt J.G.C. van, Krähenbühl M.D., Geel R.M van, Vries N. de, Rosing H., Meulendijks D., Burylo A.M., Cats A., Beijnen J.H., Huitema A.D. & Schellens J.H. (2016), Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers, British Journal of Clinical Pharmacology 82(3): 706-716.
- Meulensdijks D., Hasselt J.G.C. van, Huitema A.D.R., Tinteren H. van, Deenen M.J., Beijnen J.H., Cats A. & Schellens J.H.M. (2016), Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care, European Journal of Cancer 2016(54): 120-130.
- Illamola S.M., Colom H. & Hasselt J.G. van (2016), Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies, British Journal of Clinical Pharmacology 82(3): 793-805.
- Valitalo P.A.J., Griffioen K., Rizk M., Visser S., Danhof M., Rao M., Graaf P. & Hasselt J.G.C. van (2016), Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid, Pharmaceutical Research 33(4): 856-867.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 386--395.
- Hasselt J.C. & Graaf P.H. (2015), Towards integrative systems pharmacology models in oncology drug development, Drug Discovery Today: Technologies 15: 1--8.
- Frederix G., Severens J., Hövels A., Hasselt J., Hooiveld M., Neven P., Raaijmakers J. & Schellens J. (2015), Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium, European Journal of Cancer Care 24(3): 340--354.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 374--385.
- Yu H., Steeghs N., Kloth J.S.L., Wit D., Hasselt J.G.C. van, Erp N.P., Beijnen J.H., Schellens J.H.M., Mathijssen R.H.J. & Huitema A.D.R. (2015), Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662, British Journal of Clinical Pharmacology 79(5): 809--819.
- Hasselt J.G.C. van, Allegaert K., Calsteren K. van, Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2014), Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy, BioMed Research International 2014(Article ID 897216): 1-9DO - 10.1155/2014/897216.
- Hasselt J.G.C. van, Calsteren K., Heyns L., Han S., Mhallem Gziri M., Schellens J.H.M., Beijnen J.H., Huitema A.D.R & Amant F. (2014), Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel, Annals of Oncology 25(10): 2059--2065.
- Hasselt J.G.C. van, Eijkelenburg N.KA., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2014), Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation, Pediatric Blood & Cancer 61(12): 2223--2229.
- Hasselt J.G.C. van, Schellens J.H.M., Beijnen J.H. & Huitema A.D.R. (2014), Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error, Investigational New Drugs 32(5): 913--927.
- Klumpers L.E., Roy C., Ferron G., Turpault S., Poitiers F., Pinquier J., Hasselt J.G.C. van, Zuurman L., Erwich F.A.S. & Gerven J.M.A. van (2013), Surinabant, a selective CB(1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans, British Journal of Clinical Pharmacology 76(1): 65-77.
- Hasselt J.G.C. van, Eijkelenburg N.K.A. van, Huitema A.D.R., Schellens J.H.M. & Schouten-van Meeteren A.Y.N. (2013), Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate, Antimicrobial Agents and Chemotherapy 57(6): 2878-81.
- Hasselt J.G.C. van, Eijkelenburg N.K.A. van, Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2013), Optimizing drug development of anti-cancer drugs in children using modelling and simulation, British Journal of Clinical Pharmacology 76(1): 30-47.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2013), Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia, British Journal of Clinical Pharmacology 76(6): 2878-81.
- Frederix G.W.J., Hasselt J.G.C. van, Schellens J.H.M., Hövels A.M., Raaijmakers J.A.M., Huitema A.D.R. & Severens J.L. (2013), The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance, Pharmacoeconomics : .
- Frederix G.W.J., Hasselt J.G.C. van, Severens J.L., Hovels A.M., Huitema A.D.R., Raaijmakers J.A.M. & Schellens J.H.M. (2013), Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R, Medical Decision Making 33(6): 780-792.
- Frederix G.W.J., Severens J.L., Hövels A.M., Hasselt J.G.C. van, Raaijmakers J.A.M. & Schellens J.H.M. (2013), Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer, Breast Cancer Research and Treatment 139(2): 489-495.
- Klumpers L.E., Beumer T.L., Hasselt J.G.C. van, Lipplaa A., Karger L.B., Kleinloog D., Freijer J.I., Kam M.L. de & Gerven J.M.A. van (2012), Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects, British Journal of Clinical Pharmacology 74(1): 42-53.
- Mallaysamy S., Johnson M.G., Rao P.G.M., Rajakannan T., Bathala L., Arumugam K., Hasselt J.G.C. van & Ramakrishna D. (2012), Population pharmacokinetics of lamotrigine in Indian epileptic patients, European Journal of Clinical Pharmacology 69(1): 43-52.
- Broek M.P.H. van den, Groenendaal F., Toet M.C., Straaten H.L.M. van, Hasselt J.G.C. van, Huitema A.D.R., Vries L.S. de, Egberts A.C.G. & Rademaker C.M.A. (2012), Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia : a thermopharmacological approach, Clinical Pharmacokinetics 51(10): 671-679.
- Hasselt J.G.C. van, Green B. & Morrish G.A. (2012), Leveraging Physiological Data from Literature into a Pharmacokinetic Model to Support Informative Clinical Study Design in Pregnant Women, 29(6): 1609-1617.
- Hasselt J.G.C. van, Schellens J.H.M., Mac Gillavry M.R., Beijnen J.H. & Huitema A.D.R. (2012), Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab, 29(12): 3499-3511.
- Hasselt J.G.C. van, Heuvel M.M. van den, Schellens J.H.M., Beijnen J.H., Brandsma D. & Huitema A.D.R. (2012), Severe Cannabinoid Intoxication in a Patient with Non Small Cell Lung Cancer, Journal of palliative care 28(1): 60-61.
- Hasselt J.G.C. van, Andrew M.A., Hebert M.F., Tarning J., Vicini P. & Mattison D.R. (2012), The Status of Pharmacometrics in Pregnancy: Highlights from the 3(rd) American Conference on Pharmacometrics, British Journal of Clinical Pharmacology 74(6): 932-939.
- Broek M.P.H. van den, Huitema A.D.R., Hasselt J.G.C. van, Groenendaal F., Toet M.C., Egberts T.C.G., Vries L.S. de & Rademaker C.M.A. (2011), Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures, Clinical Pharmacokinetics 50(7): 461-469.
- Hasselt J.G.C. van, Boekhout A.H., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2011), Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity, Clinical Pharmacology & Therapeutics 90(1): 126-132.
- Krekels E.H.J., Hasselt J.G.C. van, Tibboel D., Danhof M. & Knibbe C.A.J. (2011), Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models, Pharmaceutical Research 28(4): 797-811.
- Liem-Moolenaar M., Boer P. de, Timmers M., Schoemaker R.C., Hasselt J.G.C. van, Schmidt S. & Gerven J.M.A. van (2011), Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects, British Journal of Clinical Pharmacology 71(6): 886-898.
- Dumont G.J.H., Hasselt J.G.C. van, Kam M. de, Gerven J.M.A. van, Touw D.J., Buitelaar J.K. & Verkes R.J. (2011), Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers, Journal of Psychopharmacology 25(4): 478-489.
- Lo Y.L., Hasselt J.G.C. van, Heng S.C., Lim C.T., Lee T.C. & Charles B.G. (2010), Population pharmacokinetics of vancomycin in premature malaysian neonates: identification of predictors for dosing determination, Antimicrobial Agents and Chemotherapy 54(6): 2626-2632.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U.R., Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology & Therapeutics 86(1): 44-48.
- Dumont G.J.H., Kramers C., Sweep F.C., Touw D.J., Hasselt J.G.C. van, Kam M.L. de, Gerven J.M.A. van, Buitelaar J.K. & Verkes R.J. (2009), Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans, Clinical Pharmacology & Therapeutics 86(2): 160-166.
- Organisatie wetenschappelijke bijeenkomsten
- PhD supervision and Scientific Advisor
- Penningmeester